https://vettapharma.com/pharmaceutical-news/lillys-jaypirca-cuts-cll-progression-risk-45-in-phase-3-trial/ 2026-06-23T10:02:29Z VETTAPHARMA en Lilly's Jaypirca Cuts CLL Progression Risk 45% in Phase 3 Trial 2026-06-23T10:05:00Z Blog https://vettapharma.com/pharmaceutical-news/japan-approves-sanofis-sarclisa-sc-cuts-infusion-reactions-94/ 2026-06-23T10:25:56Z VETTAPHARMA en Japan Approves Sanofi's Sarclisa SC, Cuts Infusion Reactions 94% 2026-06-23T08:00:00Z Blog https://vettapharma.com/pharmaceutical-news/sanofi-appoints-xairas-paulo-fontoura-to-lead-global-rd/ 2026-06-23T10:27:18Z VETTAPHARMA en Sanofi Appoints Xaira's Paulo Fontoura to Lead Global R&D 2026-06-23T08:00:00Z Blog https://vettapharma.com/pharmaceutical-news/roches-lunsumio-polivy-cuts-lbcl-progression-risk-59-fda-accepts-sbla/ 2026-06-22T16:45:32Z VETTAPHARMA en Roche's Lunsumio–Polivy Cuts LBCL Progression Risk 59%; FDA Accepts sBLA 2026-06-22T16:45:27Z Blog https://vettapharma.com/pharmaceutical-news/takedas-oveporexton-improves-cognition-sleep-in-phase-3-nt1-studies/ 2026-06-22T16:44:08Z VETTAPHARMA en Takeda's Oveporexton Improves Cognition, Sleep in Phase 3 NT1 Studies 2026-06-22T16:44:03Z Blog